We are developing an innovative Drug Candidate in Oncology : “First in class” & “Best in class” drug candidate with an innovative and unique mechanism of action: Inhibition of Protein Disulfide Isomerase (PDI).
Our 1st objective is to bring the drug candidate into clinical trial (Phase 1) for the treatment of human cancer within 2 years. Based on the scientific rationale, priority indication is advanced Pancreas cancer. Potential additional indications are Ovarian, Renal, Livers, and Head & Neck Cancers....
We are developing an innovative Drug Candidate in Oncology : “First in class” & “Best in class” drug candidate with an innovative and unique mechanism of action: Inhibition of Protein Disulfide Isomerase (PDI).
Our 1st objective is to bring the drug candidate into clinical trial (Phase 1) for the treatment of human cancer within 2 years. Based on the scientific rationale, priority indication is advanced Pancreas cancer. Potential additional indications are Ovarian, Renal, Livers, and Head & Neck Cancers.
More information

Employees

Pierre Goussard
Admin
Pierre Goussard CFO French CPA, working with innovative companies during the last 5 years.